HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stada's Nature's Aid Launches Sustainable Supplements In UK, Frustrated At CBD Delays

Executive Summary

HBW Insight catches up with Nature's Aid managing director Chris Morrey to talk about the firm's new sustainable dietary supplment range, Wild Earth, as well as the challenges posed by the UK's new regulstory regime for CBD novel foods. 

You may also be interested in...



GSK Signals CBD Interest With Agreement For Potential Australian Launch

GSK will evaluate the launch potential in Australia of a non-prescription CBD product currently being studied as a short-term treatment for sleep disturbances. The firm also has first refusal to negotiate the rights to market the product – developed by Cann Group – in other countries around the world.

Skin Care And VMS Propel Growth At Stada’s UK Business

Strong dermatology sales at Stada's UK Thornton & Ross subsidiary offset an almost non-existent cough and cold season, helping the business deliver almost double-digit growth in 2020, according to executive vice-president Roger Scarlett-Smith. 

‘Acquisitive and Entrepreneurial’ Stada Spies Further M&A Opportunities In US And Elsewhere

Stada Arzneimittel is looking for local partners and/or acquisition opportunities in the US to expand its offer and quickly establish its presence in the country, Stada executive vice president Roger Scarlett-Smith tells HBW Insight in this exclusive interview.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152017

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel